TY - JOUR
T1 - The effect of topical delivery of novel bisacylphosphonates in reducing alveolar bone loss in the rat model
AU - Yaffe, A.
AU - Golomb, G.
AU - Breuer, E.
AU - Binderman, I.
PY - 2000/10
Y1 - 2000/10
N2 - Background: Periodontal surgery stimulates osteoclast activity, leading to varying amounts of alveolar crest loss. We have established that topical application of 20 mg/ml of alendronate placed at the surgical mucoperiosteal site produced a striking reduction of alveolar bone loss in the rat model. The aim of this investigation was to examine the antiresorptive efficacy of 3 novel bisacylphosphonates topically delivered at the surgical site, in comparison to alendronate and etidronate which are in clinical use. Methods: Mucoperiosteal flap (MF) surgery was performed on the buccal and lingual aspects next to molars on both sides of the rat mandible. A gelatin sponge soaked in the bisphosphonate solution prepared by dissolving 20 mg of the bisphosphonate (alendronate, etidronate, VS-5, VS-6, ISA-13, SuBP) in I ml of saline was applied to exposed bone on the right side of the mandible (experimental, MF + BPs) and the left side was treated with saline only (control, MF + S). Sections were evaluated for bone loss using microradiography pattern and amount. Results: The 3 novel bisacylphosphonates, VS-5 VS-6, and ISA-13 were more effective than etidronate, and less effective than alendronate. The most effective among this group was ISA-13 followed by VS-5 and VS-6. Conclusion: We conclude that ISA-13-like alendronate is effective in reducing alveolar bone loss when delivered at surgical sites. Since ISA-13 is well absorbed through mucose tissues, we suggest that ISA-13 efficacy on reducing bone loss should be tested by its application on the mucosal tissue.
AB - Background: Periodontal surgery stimulates osteoclast activity, leading to varying amounts of alveolar crest loss. We have established that topical application of 20 mg/ml of alendronate placed at the surgical mucoperiosteal site produced a striking reduction of alveolar bone loss in the rat model. The aim of this investigation was to examine the antiresorptive efficacy of 3 novel bisacylphosphonates topically delivered at the surgical site, in comparison to alendronate and etidronate which are in clinical use. Methods: Mucoperiosteal flap (MF) surgery was performed on the buccal and lingual aspects next to molars on both sides of the rat mandible. A gelatin sponge soaked in the bisphosphonate solution prepared by dissolving 20 mg of the bisphosphonate (alendronate, etidronate, VS-5, VS-6, ISA-13, SuBP) in I ml of saline was applied to exposed bone on the right side of the mandible (experimental, MF + BPs) and the left side was treated with saline only (control, MF + S). Sections were evaluated for bone loss using microradiography pattern and amount. Results: The 3 novel bisacylphosphonates, VS-5 VS-6, and ISA-13 were more effective than etidronate, and less effective than alendronate. The most effective among this group was ISA-13 followed by VS-5 and VS-6. Conclusion: We conclude that ISA-13-like alendronate is effective in reducing alveolar bone loss when delivered at surgical sites. Since ISA-13 is well absorbed through mucose tissues, we suggest that ISA-13 efficacy on reducing bone loss should be tested by its application on the mucosal tissue.
KW - Alendronate/therapeutic use
KW - Alveolar bone loss/prevention and control
KW - Animal studies
KW - Bisphosphates/therapeutic use
KW - Comparison studies
KW - Etidronate/therapeutic use
UR - http://www.scopus.com/inward/record.url?scp=0033736370&partnerID=8YFLogxK
U2 - 10.1902/jop.2000.71.10.1607
DO - 10.1902/jop.2000.71.10.1607
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
C2 - 11063394
AN - SCOPUS:0033736370
SN - 0022-3492
VL - 71
SP - 1607
EP - 1612
JO - Journal of Periodontology
JF - Journal of Periodontology
IS - 10
ER -